STUDY

Cysteamine and hydroquinone faded melasma about the same in a tiny study

“Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.” Nguyen J et al. The Australasian journal of dermatology. February 2021

Nguyen J et al. · The Australasian journal of dermatology · February 2021

Randomized controlled trial
The finding

In a 20-person trial, melasma scores fell 21.3% with cysteamine and 32% with hydroquinone at 16 weeks, with an uncertain difference.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized and double-blind. Each participant got two creams, one active and one without the active ingredient. Everyone washed off the first cream after 15 minutes and left the second on.
At a glance

Who was studied and for how long

Randomized
20 women
14 completed per protocol
Length
16 weeks
One center in Australia
Compared
Two creams
5% cysteamine vs 4% hydroquinone
Shared care
Sunscreen
Both groups
What they did

How the study worked

20 womenmelasmaRANDOMSPLIT5% cysteamine10 assigned15-minute contact4% hydroquinone10 assignedleave-on creamMEASURED ATWeek 16melasma score20 womenmelasmaRANDOMSPLIT5% cysteamine10 assigned · 15-minute contact4% hydroquinone10 assigned · leave-on creamMEASURED ATWeek 16melasma score
Random assignmentTen women were assigned to each treatment. Both groups were given the same sunscreen.
Two-step routineThe first cream was washed off after 15 minutes. The second stayed on. Only one cream contained the active treatment in each group.
Score melasmaClinicians compared changes in melasma severity at weeks 8 and 16.
What they found

The results

5% cysteamine4% hydroquinone

Drop in melasma score at week 16

Percentage reduction from baseline in the analysis of all randomized participants.

Cysteamine
21.3%
Hydroquinone
32%
No clear difference (p = 0.30)
Hydroquinone had the larger numerical improvement in the main analysis and was generally better tolerated. The sample was too small to establish that the creams work equally well.
Who paid for it

Funding and conflicts of interest

Scientis Pharma funded the trial, and a pharmacist from the company generated the random assignments. The authors declared no conflicts of interest.

How much to trust it

Strengths and limits

Strengths

  • Double-blind randomized comparison
  • Used a standard melasma severity score
  • Compared with an active treatment

Limits

  • Only 20 women at one center
  • Six participants did not complete the protocol
  • Follow-up ended at 16 weeks
Limited confidence. Only 20 women entered the trial, and six did not complete it as planned. The study could miss a meaningful difference.
What it means for you

The takeaway

Uncertain difference

Both groups improved. The study was too small to establish whether the size of the improvement differed between creams.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

mMASI

A score based on the area and darkness of melasma patches.

Original source

Nguyen J, Remyn L, Chung IY, Honigman A, Gourani-Tehrani S, Wutami I, Wong C, Paul E, Rodrigues M. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.. Australas J Dermatol. 2021;62(1):e41-e46.

PMID 32981068